[Pharmacotherapy of generalized anxiety disorder: state of the art].
A large percentage of patients in primary care suffer from Generalized Anxiety Disorder (GAD). A task force of the Swiss GAD Society has reviewed the scientific literature and has developed treatment recommendations. Basic treatment, adjunctive treatment and therapy of specific problems like insomnia and comorbidities are differentiated. Newer antidepressants are recommended as basic treatment, especially venlafaxine and paroxetine, which are licensed for that indication.
Zullino
D F
DF
Département Universitaire de Psychiatrie Adulte, Prilly-Lausanne. Daniele.Zullino@inst.hospvd.ch
Hättenschwiler
J
J
Mattia
M
M
Stankovic
M
M
Khazaal
Y
Y
Borgeat
F
F
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003511:Cyclohexanols / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D015201:Meta-Analysis as Topic; D017374:Paroxetine / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D013997:Time Factors; D000069470:Venlafaxine Hydrochloride
D014151:Anti-Anxiety Agents; D018687:Antidepressive Agents, Second-Generation; D001569:Benzodiazepines; D003511:Cyclohexanols; D017374:Paroxetine; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride